1-(4-chlorophenyl)cyclobutanecarbohydrazide | 633317-84-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-chlorophenyl)cyclobutanecarbohydrazide
• 英文别名: 1-(4-chlorophenyl)cyclobutane-1-carbohydrazide
• CAS: 633317-84-7
• 化学式: C₁₁H₁₃ClN₂O
• mdl: MFCD25965595
• 分子量: 224.69
• InChiKey: XPKKOQWZSYNFTG-UHFFFAOYSA-N

物化性质

• 沸点：
  412.7±34.0 °C(Predicted)
• 密度：
  1.300±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-chlorophenyl)cyclobutanecarbohydrazide 、 methyl 4-iodo-N-methylbenzimidate 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 3-(1-(4-chlorophenyl)cyclobutyl)-5-(4-iodophenyl)-4-methyl-4H-1,2,4-triazole
  参考文献：
  名称：

  4-Methyl-5-phenyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I

  摘要：

  4-Methyl-5-phenyl-(1,2,4)-triazoles were identified as selective inhibitors of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). They were active in vitro and in an in vivo mouse pharmacodynamic (PD) model. The synthesis and structure activity relationships are presented. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.013
• 作为产物：
  描述：

  1-(4-chlorophenyl)cyclobutanecarbonyl fluoride 在 三乙胺 、 肼 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 1-(4-chlorophenyl)cyclobutanecarbohydrazide
  参考文献：
  名称：

  [EN] 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA
  [FR] INHIBITEURS DE LA 11-BETA-HYDROXYSTEROIDE DESHYDROGENASE 1 UTILISABLES POUR LE TRAITEMENT DU DIABETE, DE L'OBESITE ET DE LA DYSLIPIDEMIE

  摘要：

  公开号：

  WO2003104207A3

文献信息

• 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
  申请人：——

  公开号：US20040106664A1

  公开（公告）日：2004-06-03

  Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof: 1 are selective inhibitors of the 11&bgr;-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidernia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.

  具有I式的化合物，包括药物可接受的盐、水合物和溶剂化合物：1是11&bgr;-HSD1酶的选择性抑制剂。这些化合物可用于治疗糖尿病，如非胰岛素依赖性糖尿病（NIDDM），高血糖，肥胖症，胰岛素抵抗，血脂异常，高脂血症，高血压，X综合征以及与NIDDM相关的其他症状。
• 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA
  申请人：——

  公开号：US20040048912A1

  公开（公告）日：2004-03-11

  Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof: 1 are selective inhibitors of the 11&bgr;-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.

  式I的化合物，包括药学上可接受的盐、水合物和溶剂化物：1是11β-HSD1酶的选择性抑制剂。这些化合物可用于治疗糖尿病，如非胰岛素依赖性糖尿病（NIDDM）、高血糖、肥胖症、胰岛素抵抗、脂质代谢紊乱、高脂血症、高血压、X综合症以及与NIDDM相关的其他症状。
• 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
  申请人：Merck & Co., Inc.

  公开号：US07179802B2

  公开（公告）日：2007-02-20

  Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof: are selective inhibitors of the 11β-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidernia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.

  具有I式的化合物，包括其药学上可接受的盐、水合物和溶剂化物：是11β-HSD1酶的选择性抑制剂。这些化合物可用于治疗糖尿病，如非胰岛素依赖性糖尿病（NIDDM）、高血糖、肥胖症、胰岛素抵抗、血脂异常、高脂血症、高血压、X综合症以及与NIDDM相关的其他症状。
• 11-&bgr;-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
  申请人：Merck & Co., Inc.

  公开号：US06730690B2

  公开（公告）日：2004-05-04

  Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof: are selective inhibitors of the 11&bgr;-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.

  具有I式的化合物，包括其药学上可接受的盐、水合物和溶剂化合物：是11β-HSD1酶的选择性抑制剂。这些化合物对于治疗糖尿病，如非胰岛素依赖性糖尿病（NIDDM）、高血糖、肥胖症、胰岛素抵抗、血脂异常、高血脂症、高血压、X综合症以及与NIDDM相关的其他症状非常有用。
• Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists
  作者：Jong Yup Kim、Hee Jeong Seo、Sung-Han Lee、Myung Eun Jung、Kwangwoo Ahn、Jeongmin Kim、Jinhwa Lee

  DOI：10.1016/j.bmcl.2008.10.130

  日期：2009.1

  Since the CB1 receptor antagonist SR141716 (rimonabant) was reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target in the treatment of obesity. Several series of derivatives based on diarylimidazolyl oxadiazole and thiadiazole scaffolds were synthesized and tested for CB1 receptor binding affinity. SAR studies directed toward the optimization of imidazole scaffolds resulted in the discovery of 10s which showed highest potency for CB1 receptor binding affinity (IC50 = 1.91 nM) prepared to date. (C) 2008 Elsevier Ltd. All rights reserved.